<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
    /* References section styling */
    .refs-section { border: 1px solid var(--border); border-radius: 12px; padding: 16px; background: var(--card); }
    .refs-title { font-size: 16px; font-weight: 700; color: #1f2937; margin: 0 0 16px 0; padding-bottom: 8px; border-bottom: 2px solid var(--accent); }
    .ref-category { margin-bottom: 16px; }
    .ref-cat-header { font-size: 14px; font-weight: 600; color: #374151; margin-bottom: 10px; padding: 6px 10px; background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%); border-radius: 6px; }
    .ref-entry { margin-bottom: 10px; padding: 10px 12px; background: #fafafa; border-radius: 8px; border-left: 3px solid var(--accent); }
    .ref-tag { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, monospace; font-size: 12px; font-weight: 600; color: var(--accent); margin-bottom: 6px; word-break: break-all; }
    .ref-details { font-size: 13px; color: #4b5563; line-height: 1.6; }
    .ref-detail-line { margin-bottom: 2px; }
    /* Category-specific colors */
    .ref-guidelines .ref-entry { border-left-color: #059669; }
    .ref-guidelines .ref-tag { color: #059669; }
    .ref-literature .ref-entry { border-left-color: #7c3aed; }
    .ref-literature .ref-tag { color: #7c3aed; }
    .ref-clinical-trials .ref-entry { border-left-color: #dc2626; }
    .ref-clinical-trials .ref-tag { color: #dc2626; }
    .ref-clinical-reports .ref-entry { border-left-color: #d97706; }
    .ref-clinical-reports .ref-tag { color: #d97706; }
    /* Mermaid chart styling */
    .mermaid-container { border-color: #10b981; }
    .mermaid-container > summary { color: #059669; }
    .mermaid-chart { padding: 16px; background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%); border-radius: 10px; margin-top: 10px; overflow-x: auto; }
    .mermaid-chart svg { max-width: 100%; height: auto; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class='card stats-card' style='background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9; margin-bottom: 16px;'>
<h2 style='margin-top: 0; color: #0369a1;'>ğŸ“Š Pipeline Execution Statistics</h2>
<div style='margin-bottom: 12px;'>
<strong>â±ï¸ Total Execution Time:</strong> 141.1 seconds (2åˆ†21ç§’)
</div>
<div style='margin-bottom: 12px;'>
<strong>ğŸ”¢ Total Tokens:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li>Input: 116,280</li>
<li>Output: 5,107</li>
<li>Total: 121,387</li>
</ul>
</div>
<div style='margin-bottom: 8px;'>
<strong>ğŸ¤– Models Used:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li style='margin-bottom: 6px;'>
<strong>gpt-5.1 (Azure)</strong>: 
23 calls, 
121,387 tokens 
(116,280 in / 5,107 out)
</li>
</ul>
</div>
</div>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-21_07-03-43</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Highâ€‘grade ovarian clear cell carcinoma, platinumâ€‘resistant, with progressive hepatic and presacral/sacral/iliac bone metastases and severe anemia; main uncertainties are performance status, anemia etiology, and trial options.

Core Treatment Strategy:
- Immediately investigate and correct anemia (iron/B12/folate, hemolysis, transfusion as needed) before further systemic therapy [@20230103|5600862 | LAB].  
- Document ECOG status, pain (including bone/neurologic), and prior toxicity to define feasible nonâ€‘platinum relapseâ€‘therapy intensity [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].  
- Plan nonâ€‘platinum systemic relapse therapy for platinumâ€‘resistant clear cell disease once optimized; parallelly screen for eligible phase Ib/II trials [@OH2203828 | Genomics][@pubmed | 30109783][@trial | 350].  
- Use 2022â€‘12â€‘29 CT/MR as staging baseline; repeat CT/MR if clinical status changes, reserving PETâ€‘CT only if results would alter systemic or palliative local strategies [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].  

Change Triggers:
- If anemia persists or worsens despite workâ€‘up/treatment, delay or deâ€‘escalate systemic therapy intensity and prioritize supportive measures.  
- If new focal bone/neurologic symptoms or rapid marker rise occur, obtain urgent targeted imaging and consider palliative radiotherapy or adjusted systemic approach.</pre>
<div class='refs-section mt'>
<h3 class='refs-title'>References</h3>
<div class='ref-category ref-guidelines'>
<div class='ref-cat-header'>ğŸ“‹ Guidelines</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 10</div>
<div class='ref-detail-line'>Content: with ï¬rst line. This can probably be explained by an...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: esgo_esmo_esp_consensus_ovariancancer_2024__v00000000, Page 8</div>
<div class='ref-detail-line'>Content: [III, B].</div>
<div class='ref-detail-line'>Consensus: 97% (34) yes, 0% (0) no, 3% (1)...</div>
</div>
</div>
</div>
<div class='ref-category ref-literature'>
<div class='ref-cat-header'>ğŸ“š Literature</div>
<div class='ref-entry'>
<div class='ref-tag'>[@pubmed | 30109783]</div>
<div class='ref-details'>
<div class='ref-detail-line'>PMID: 30109783 | Cancer Med | 2018-09-01</div>
<div class='ref-detail-line'>Title: Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.</div>
<div class='ref-detail-line'>DOI: 10.1002/cam4.1724</div>
</div>
</div>
</div>
<div class='ref-category ref-clinical-trials'>
<div class='ref-cat-header'>ğŸ”¬ Clinical Trials</div>
<div class='ref-entry'>
<div class='ref-tag'>[@trial | 350]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Trial ID: 350</div>
<div class='ref-detail-line'>Name: è¯„ä»·æ³¨å°„ç”¨BL-B01D1åœ¨å¤å‘æˆ–è½¬ç§»æ€§å¦‡ç§‘æ¶æ€§è‚¿ç˜¤ç­‰å¤šç§å®ä½“ç˜¤æ‚£è€…ä¸­çš„å®‰å…¨æ€§ã€è€å—æ€§ã€è¯ä»£åŠ¨åŠ›å­¦åŠæœ‰æ•ˆæ€§çš„Ib/IIæœŸä¸´åºŠç ”ç©¶</div>
<div class='ref-detail-line'>Rationale: Recurrent metastatic ovarian clear cell carcinoma is a gynecologic malignancy after â‰¥1 prior standard therapy, matching this 2Lâ€“3L gynecologic trial without biomarker requirements.</div>
</div>
</div>
</div>
<div class='ref-category ref-clinical-reports'>
<div class='ref-cat-header'>ğŸ“„ Clinical Reports</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230103|5600862 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230103|5600862 | Date: 2023-01-03</div>
<div class='ref-detail-line'>Content: ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN) PLTåˆ†å¸ƒå®½åº¦ 12 % (PDW) å—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@OH2203828 | Genomics]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Genomics ID: OH2203828 | Date: 2022-04-18</div>
<div class='ref-detail-line'>Content: ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-12-29|MR | MR]</div>
<div class='ref-details'>
<div class='ref-detail-line'>MR ID: 2022-12-29|MR | Date: 2022-12-29</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-12-29|CT | CT]</div>
<div class='ref-details'>
<div class='ref-detail-line'>CT ID: 2022-12-29|CT | Date: 2022-12-29</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§...</div>
</div>
</div>
</div>
</div>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰æœ¯åç™½ç´«+å¡é“‚åŒ–ç–—6ç¨‹ï¼Œæœ«æ¬¡ï¼š2022.8.172022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)MRï¼ˆ2022.07.17ï¼‰ï¼š2022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.10.12ï¼‰ï¼šCA19-9:77.20U/mlâ†‘,CA125:89.60U/mlâ†‘,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(ç»ç»å‰)â†‘,ROMA.:36.67%(ç»ç»å)â†‘ã€‚CTï¼ˆ2022.10.25ï¼‰ï¼šè‚å†…å¤šå‘ç»“èŠ‚ï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ï¼Œè½¬ç§»å¯èƒ½ï¼Œè¯·ç»“åˆMRæ£€æŸ¥ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚MRï¼ˆ2022.10.24ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚2022.11.10å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 2.36ï¼Œçº¢ç»†èƒ 3.56ï¼Œè¡€çº¢è›‹ç™½ 97ï¼Œè¡€å°æ¿ 153å¤–é™¢ç”ŸåŒ–ï¼šALPã€€105ï¼ŒNA 136ï¼ŒPAB 1242022.11.30å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 3.46ï¼Œçº¢ç»†èƒ 3.48ï¼Œè¡€çº¢è›‹ç™½ 94ï¼Œè¡€å°æ¿ 1342022.11.17å¤–é™¢è‚¿ç˜¤æŒ‡æ ‡ï¼šCA125ã€€403ï¼ŒCa153ã€€63.8ï¼ŒCa199 96.8ï¼ŒCa724 695è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.12.29ï¼‰ï¼šCA19-9:229.00U/mlâ†‘,CA125:933.00U/mlâ†‘,CA15-3:86.00U/mlâ†‘,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/Lâ†‘,ROMA:41.02%(ç»ç»å‰)â†‘,ROMA.:85.98%(ç»ç»å)â†‘ã€‚MRï¼ˆ2022.12.30ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚CTï¼ˆ2022.12.30ï¼‰ï¼šè‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚å’¨è¯¢æŠ¥å‘Š</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;High-grade adenocarcinoma involving full-thickness intestinal wall&quot;,&quot;Lymph node metastasis (4/15)&quot;,&quot;Peritoneal/rectal/vaginal involvement described&quot;],&quot;histology&quot;:&quot;é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;åµå·¢ç™Œå¤å‘&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Unknown&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;ç™½ç´«+å¡é“‚&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;Rise in CA125/CA19-9 on 2022-10-12&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery performed&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with rising tumor markers&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;6 cycles of ç™½ç´«+å¡é“‚, last 2022-08-17&quot;,&quot;last_admin_date&quot;:&quot;2022-08-17&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;Tumor size ~7x4x2.5 cm&quot;,&quot;Bilateral margins negative&quot;,&quot;Pericolic lymph nodes 4/15 positive&quot;,&quot;One tumor nodule (posterior bladder)&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;partial+&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;few weak+&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;+/-&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;60%+&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;focal+&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;-&quot;}],&quot;involvement_sites&quot;:[&quot;Rectosigmoid colon&quot;,&quot;Left retroperitoneum&quot;,&quot;Vagina&quot;,&quot;Pericolic lymph nodes&quot;,&quot;Posterior bladder nodule&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562 2022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;Partial rectosigmoid + left retroperitoneal tumor + partial vagina&quot;,&quot;tumor_size&quot;:&quot;7 x 4 x 2.5 cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;BRCA/HRD testing not reported&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules&quot;],&quot;impression&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple intrahepatic nodules, some new compared to prior&quot;],&quot;impression&quot;:&quot;Probable metastases in liver&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis; sacrum; right iliac bone&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar&quot;],&quot;impression&quot;:&quot;Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver; spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct&quot;],&quot;impression&quot;:&quot;Progression of hepatic metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: 350
- name: è¯„ä»·æ³¨å°„ç”¨BL-B01D1åœ¨å¤å‘æˆ–è½¬ç§»æ€§å¦‡ç§‘æ¶æ€§è‚¿ç˜¤ç­‰å¤šç§å®ä½“ç˜¤æ‚£è€…ä¸­çš„å®‰å…¨æ€§ã€è€å—æ€§ã€è¯ä»£åŠ¨åŠ›å­¦åŠæœ‰æ•ˆæ€§çš„Ib/IIæœŸä¸´åºŠç ”ç©¶
- Reason: Recurrent metastatic ovarian clear cell carcinoma is a gynecologic malignancy after â‰¥1 prior standard therapy, matching this 2Lâ€“3L gynecologic trial without biomarker requirements.
- Missing eligibility confirmations (0-2 items):
  - Confirmation of ECOG performance status and other general organ function criteria
  - Confirmation that there is no other available standard systemic therapy deemed appropriate by treating physician</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round Ã— Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before finalizing a nonâ€‘platinum regimen, we must correct severe anemia and document ECOG and prior toxicities; otherwise regimen intensity decisions risk excess toxicity [@20230103|5600862 | LAB].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please confirm whether any CT/MRI after 2022â€‘12â€‘29/30 exist and, if not, whether PETâ€‘CT would realistically change local vs systemic planning [@2022-12-29|MR] [@2022-12-29|CT].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>Kindly clarify in the report whether any features suggest alternative histotype or mixed tumor, as this could alter systemic strategy [@2022-03-28 | CT].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>Given already clear hepatic and bone metastases on CT/MRI, please advise if PETâ€‘CT would add actionable information beyond current staging [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before committing to a specific nonâ€‘platinum systemic strategy, I need ECOG status, detailed symptom burden, and prior toxicity profile to judge tolerability and dose intensity; anemia workâ€‘up and transfusion plan should be clarified urgently to avoid underâ€‘ or overdosing cytotoxic therapy in the context of Hgb 74 g/L. [@20230103|5600862 | LAB]</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>chair</td><td>Imaging facts in the MDT summary (widespread hepatic and pelvic osseous disease) match only the 2022-12-29 CT/MR; please confirm there is no more recent CT/MRI, otherwise updated scans are needed to guide current decisions [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>From pathology side, key missing item is a detailed NGS interpretive report classifying the germline ATM p.Y316C variant (pathogenic vs VUS) and commenting on trial eligibility. [@OH2203828 | Genomics]</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>From nuclear perspective, no actual PET report is available; if PET-CT is intended to guide further local measures, please confirm whether any PET has been performed after 2022-12-29 cross-sectional imaging or explicitly schedule one, as current staging relies solely on MRI/CT [@2022-12-29|MR | MR][@2022-12-29|CT | CT].</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Platinumâ€‘resistant metastatic clear cell ovarian carcinoma with rapid progression in liver, presacral/sacral and bone; systemic nonâ€‘platinum regimen indicated [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].  \n\n- Baseline anemia (Hgb 74 g/L) requires correction and transfusion/iron assessment before starting further systemic therapy [@20230103|5600862 | LAB].  \n\n- Before firm plan: document ECOG status, pain/skeletal symptoms, prior toxicities, and confirm current MRI/CT images and full NGS interpretation details [@OH2203828 | Genomics].&quot;,
  &quot;oncologist&quot;: &quot;- Platinum-resistant recurrent clear cell ovarian carcinoma with rising CA125/CA19-9 and new liver/bone metastases; systemic relapse-therapy category indicated. [@20221229|9703212 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \n\n- Significant anemia (Hgb 74 g/L) may limit intensity of cytotoxic systemic therapy; requires optimization/transfusion before full-dose treatment. [@20230103|5600862 | LAB]  \n\n- Organ function (renal/hepatic) appears acceptable for most systemic options; confirm current performance status and recent cross-sectional imaging details for planning. [@20221229|8300002 | LAB]&quot;,
  &quot;radiologist&quot;: &quot;- Progressive presacral pelvic mass with sacral and right iliac bone involvement; multiple stable pelvic mesenteric/peritoneal nodules suspicious for metastases [@2022-10-24|MR | MR] [@2022-12-29|MR | MR].  \n\n- Liver: multiple metastatic nodules increasing in number and size; spleen with patchy lowâ€‘density area possibly infarct, needs clinical correlation [@2022-12-29|CT | CT].  \n\n- Crossâ€‘sectional CT/MRI adequately demonstrate advanced, recurrent disease distribution for MDT treatment planning [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].&quot;,
  &quot;pathologist&quot;: &quot;- Morphology and IHC strongly support recurrent ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina, highâ€‘grade. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]\n\n- MMR proteins intact; no evidence of MMR deficiency/MSIâ€‘H on IHC. [@2022-03-28 | LAB]\n\n- Comprehensive NGS: germline ATM p.Y316C; BRCA1/2 and HRD negative; no other pathogenic HRR variants detected. [@OH2203828 | Genomics]&quot;,
  &quot;nuclear&quot;: &quot;- Known pelvic presacral mass with sacral and right iliac bone involvement; PET could better define osseous/metastatic extent and activity [@2022-12-29|MR | MR].\n\n- Progressive multifocal hepatic metastases on CT; PET would refine wholeâ€‘body metastatic burden and extrahepatic disease mapping [@2022-12-29|CT | CT].\n\n- For advanced/recurrent ovarian carcinoma, PETâ€‘CT is an acceptable staging option complementing MRI/CT for planning [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Correct severe anemia and clarify ECOG, symptom burden, prior toxicities before initiating any nonâ€‘platinum systemic therapy [@20230103|5600862 | LAB].  \n\n- Proceed with nonâ€‘platinum systemic regimen suitable for platinumâ€‘resistant clear cell disease once optimized, considering trial options and ATMâ€‘related eligibility [@OH2203828 | Genomics][@pubmed | 30109783].  \n\n- Update staging with latest CT/MRI; add PETâ€‘CT only if results would change systemic versus palliative local strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].&quot;,
    &quot;oncologist&quot;: &quot;- Correct anemia and document ECOG, symptom burden, and prior toxicities before initiating individualized nonâ€‘platinum relapse systemic therapy. [@20230103|5600862 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \n\n- Proceed with systemic relapseâ€‘therapy planning assuming clear cell histology, MMR proficiency, BRCA/HRD negativity, and germline ATM variant per NGS. [@OH2203828 | Genomics] [@pubmed | 30109783]  \n\n- Confirm no postâ€‘2022â€‘12â€‘29 CT/MRI; order PETâ€‘CT only if results would modify systemic choice or local palliative interventions. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]&quot;,
    &quot;radiologist&quot;: &quot;- No crossâ€‘sectional imaging is available after 2022â€‘12â€‘29; current staging relies on that CT/MR set [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].  \n\n- Before PETâ€‘CT, clarify whether updated CT/MR is planned; PET should be reserved for scenarios where it may alter management [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].  \n\n- Document any new focal bone or neurologic symptoms to prioritize targeted imaging (e.g., spine/pelvis MRI) if clinically indicated [@2022-12-29|MR | MR].&quot;,
    &quot;pathologist&quot;: &quot;- Confirm final histology as pure highâ€‘grade ovarian clear cell carcinoma; no morphologic evidence of mixed or alternative histotype. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]\n\n- Clearly state MMR proficiency (MLH1/MSH2/MSH6/PMS2 retained) and ER/PR focal expression in the pathology addendum. [@2022-03-28 | LAB]\n\n- Request integrated molecular addendum summarizing HRDâ€‘negative, BRCAâ€‘wildâ€‘type status and detailing germline ATM p.Y316C classification/implications. [@OH2203828 | Genomics]&quot;,
    &quot;nuclear&quot;: &quot;- No PET-CT yet; recommend wholeâ€‘body FDG PET-CT only if updated mapping would alter local palliation or systemic strategy [@2022-12-29|MR | MR][@2022-12-29|CT | CT][@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8].\n\n- Current staging rests on 2022-12-29 CT/MR showing progressive liver and presacral/sacral disease; repeat crossâ€‘sectional imaging before PET if outdated [@2022-12-29|MR | MR][@2022-12-29|CT | CT].\n\n- When performed, PET interpretation should focus on defining true osseous and extrahepatic metastatic burden beyond MRI/CT, to refine radiotherapy targeting [@2022-12-29|MR | MR][@2022-12-29|CT | CT].&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;å¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 43.0 U/L (AST)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.09 mmol/L (NEFA)\nè°·æ°¨é…¸è„±æ°¢é…¶ 4.1 U/L (GLDH)\nç™½è›‹ç™½ 36.7 g/l (ALB)\næ€»è›‹ç™½ 67.0 g/l (TP)\nè°·è‰åŒå·¥é…¶ 12.7 U/L (ASTM)\nçƒè›‹ç™½ 30.3 g/l (GELO)\nç›´æ¥èƒ†çº¢ç´  3.2 umol/l (DBIL)\nå°¿é…¸ 146 umol/l (UA)\næ€»èƒ†çº¢ç´  5.1 umol/l (TBIL)\nå‰ç™½è›‹ç™½ 98 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  1.9 umol/L (IBIL)\nç¢±æ€§ç£·é…¸é…¶ 100.0 U/L (ALP)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 40.8 U/l (ALT)\nè‚Œé… 49 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.21 nan (A/G)\nä¹³é…¸è„±æ°¢é…¶ 254 U/L (LDH)\nå°¿ç´  4.67 mmol/l (UREA)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;å¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 43.0 U/L (AST)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.09 mmol/L (NEFA)\nè°·æ°¨é…¸è„±æ°¢é…¶ 4.1 U/L (GLDH)\nç™½è›‹ç™½ 36.7 g/l (ALB)\næ€»è›‹ç™½ 67.0 g/l (TP)\nè°·è‰åŒå·¥é…¶ 12.7 U/L (ASTM)\nçƒè›‹ç™½ 30.3 g/l (GELO)\nç›´æ¥èƒ†çº¢ç´  3.2 umol/l (DBIL)\nå°¿é…¸ 146 umol/l (UA)\næ€»èƒ†çº¢ç´  5.1 umol/l (TBIL)\nå‰ç™½è›‹ç™½ 98 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  1.9 umol/L (IBIL)\nç¢±æ€§ç£·é…¸é…¶ 100.0 U/L (ALP)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 40.8 U/l (ALT)\nè‚Œé… 49 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.21 nan (A/G)\nä¹³é…¸è„±æ°¢é…¶ 254 U/L (LDH)\nå°¿ç´  4.67 mmol/l (UREA)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2022-7-16ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œç›¸é‚»éª¶éª¨å—ç´¯ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšï¼Œè†€èƒ±å†…å¯ç–‘å°‘è®¸ç§¯æ°”æœ¬æ¬¡ä¸æ˜æ˜¾ã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2022-7-16ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œç›¸é‚»éª¶éª¨å—ç´¯ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšï¼Œè†€èƒ±å†…å¯ç–‘å°‘è®¸ç§¯æ°”æœ¬æ¬¡ä¸æ˜æ˜¾ã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2022-7-16ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œç›¸é‚»éª¶éª¨å—ç´¯ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšï¼Œè†€èƒ±å†…å¯ç–‘å°‘è®¸ç§¯æ°”æœ¬æ¬¡ä¸æ˜æ˜¾ã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>Recurrent platinum-resistant ovarian clear cell carcinoma with pelvic, presacral, liver and possible bone metastases; Ki-67 60%; HRD-negative, BRCA1/2-negative, germline ATM p.Y316C; no major organ dysfunction reported; histology: clear cell carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6275 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 6] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]
    carcinoma demonstrated that adjuvant platinum-based ChT prolonged survival, but did not prospectively evaluate his- tological subtypes.38,39 High-grade EC has a similar prog- nosis to HGSC and is worse than low-grade EC. It is not clear whether there is any survival beneï¬t for adjuvant ChT in stage â€¦
[2] score=0.6256 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 17] [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17]
    17 Table 1 Indications for in vivo ovarian tissue preservation in ovarian neoplasms according to the histological type and the stage of the disease STAGE EPITHELIAL OVARIAN NEOPLASMS NON-EPITHELIAL OVARIAN NEOPLASMS BOT1 LGSC LGEC MCexp CCC HGSC HGEC MCinf GCT2 SCC GrCT SLCT3 SLCT4 IA IB IC1 IC2 ## â€¦
[3] score=0.6196 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 8] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8]
    [III, B]. Consensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35 voters) Recommendation 11.7: Contrast-enhanced CT, MRI and PETeCT with a structured radiology report are considered as options for the initial evaluation of patients with advanced ovarian carcinoma [III, A]. US by an expert so- nographâ€¦
[4] score=0.6155 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 17] [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17]
    to the use of ovarian preservation itself and/or the natural history of the disease (whatever the preservation or not of the ovary) in these patients having poorest prognostic factors). 1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac tumours; 3well and moderatâ€¦
[5] score=0.6151 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]
    with ï¬rst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected â€¦

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.6896 PMID 30109783 [@pubmed | 30109783]
    Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.
    NUCOLL43 is a novel ovarian clear cell carcinoma (O-CCC) cell line that arose from a primary culture of a patient&#x27;s malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45Â hours and form colonies at high efficiency. They have a very high degree of loss of heteroâ€¦
[2] score=0.6798 PMID 33376347 [@pubmed | 33376347]
    Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic
    Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1-2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation sâ€¦
[3] score=0.6725 PMID 26774475 [@pubmed | 26774475]
    Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
    High-grade serous ovarian carcinomas (HGSOCs) with BRCA1/2 mutations exhibit improved outcome and sensitivity to double-strand DNA break (DSB)-inducing agents (i.e., platinum and poly(ADP-ribose) polymerase inhibitors [PARPis]) due to an underlying defect in homologous recombination (HR). However, râ€¦
[4] score=0.6686 PMID 38555285 [@pubmed | 38555285]
    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
    The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with measurable and biâ€¦
[5] score=0.6674 PMID 36591227 [@pubmed | 36591227]
    Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.
    Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radiâ€¦</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6275324821472168,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 6,
    &quot;text&quot;: &quot;carcinoma demonstrated that adjuvant platinum-based ChT\nprolonged survival, but did not prospectively evaluate his-\ntological subtypes.38,39 High-grade EC has a similar prog-\nnosis to HGSC and is worse than low-grade EC. It is not clear\nwhether there is any survival beneï¬t for adjuvant ChT in\nstage IA or IB CCC.40,41\nRecommendation\n7.1:\nComplete\nsurgical\nresection\nincluding total abdominal hysterectomy, bilateral salpingo-\noophorectomy, omentectomy, systematic pelvic and para-\naortic lymph node dissection, peritoneal biopsies and\ncytological analysis should be the standard surgical pro-\ncedure in stage I-II high-grade EC, CCC and high-risk\nmucinous ovarian carcinoma [IV, A].\nConsensus: 97% (38) yes, 3% (1) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.2: Patients with stage I-II high-grade\nEC should be offered adjuvant platinum-based ChT [IV, A].\nConsensus: 100% (39) yes, 0% (0) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.3: Adjuvant ChT may be omitted for\nadequately staged IA or IB CCC [IV, C].\nConsensus: 90% (35) yes, 5% (2) no, 5% (2) abstain (39\nvoters)\nRecommendation 7.4: Adjuvant ChT may be considered\nfor stage IC1 CCC [IV, C].&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6256052851676941,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;17\nTable 1\nIndications for in vivo ovarian tissue preservation in ovarian\nneoplasms according to the histological type and the stage\nof the disease\nSTAGE\nEPITHELIAL OVARIAN NEOPLASMS\nNON-EPITHELIAL OVARIAN NEOPLASMS\nBOT1\nLGSC\nLGEC\nMCexp\nCCC\nHGSC\nHGEC\nMCinf\nGCT2\nSCC\nGrCT\nSLCT3\nSLCT4\nIA\nIB\nIC1\nIC2\n##\nIC3\n##\nII-IV\n#\n\nfavourable oncologic selection criteria for fertility-sparing management as defined in\nthe text (based on the favourable survival and/or recurrence rates observed in cohorts and/\nor comparative studies (radical versus conservative) of patients treated with such characteris-\ntics).\n\noncologic selection criteria acceptable in selected cases (insufficient or conflicting data\nto evaluate accurately the results of the ovarian preservation in this subgroup of patients).\n\nunfavourable oncologic selection criteria for ovarian preservation (poorest survival\nobserved in patients having an ovarian preservation in these subgroups. It could be related\nto the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6196172833442688,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 8,
    &quot;text&quot;: &quot;[III, B].\nConsensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35\nvoters)\nRecommendation 11.7: Contrast-enhanced CT, MRI and\nPETeCT with a structured radiology report are considered\nas options for the initial evaluation of patients with\nadvanced ovarian carcinoma [III, A]. US by an expert so-\nnographer may be used to assess tumour extent and\nresectability in the pelvis and abdominal cavity [III, C].\nJ. A. Ledermann et al.\nAnnals of Oncology\nVolume 35&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6154544949531555,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;to the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).\n1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac\ntumours; 3well and moderately differentiated; 4poorly differentiated; #for grade 2-3 imma-\nture teratoma stage II-IV, fertility-sparing data are limited; ## for Sertoli-Leydig cell tumour\nstage IC2-3, fertility-sparing data are limited.\nBOT borderline ovarian tumour; CCC clear cell carcinoma; GCT germ cell tumour; GrCT\ngranulosa cell tumour; HGEC high-grade endometrioid carcinoma; HGSC high-grade serous\ncarcinoma; LGSC low-grade serous carcinoma; LGEC low-grade endometrioid carcinoma,\nMCexp mucinous carcinoma with expansile invasion, MCinf mucinous carcinoma with in-\nfiltrative invasion; SCC small cell carcinoma; SLCT Sertoli-Leydig cell tumour.&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6150704622268677,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ï¬rst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciï¬cally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6896477654221516,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;30109783&quot;,
    &quot;title&quot;: &quot;Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.&quot;,
    &quot;abstract&quot;: &quot;NUCOLL43 is a novel ovarian clear cell carcinoma (O-CCC) cell line that arose from a primary culture of a patient&#x27;s malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45Â hours and form colonies at high efficiency. They have a very high degree of loss of heterozygosity (LOH) affecting approximately 85% of the genome, mostly copy neutral and almost identical to the original tumor. The cells express epithelial (pan-cytokeratin) and mesenchymal (vimentin) characteristics, CA125 and p16, like the original tumor. They also express ARID1A but not HNF-1Î² and, like the original tumor, and are negative for p53 expression, with no evidence of p53 function. NUCOLL43 cells express all other DNA damage response proteins investigated and have functional homologous recombination DNA repair. They are insensitive to cisplatin, the PARP inhibitor rucaparib, and MDM2 inhibitors but are sensitive to camptothecin, paclitaxel, and NVP-BEZ235. The NUCOLL43 cell line represents a distinct subtype of O-CCC that is p53 and HNF-1Î² null but expresses ARID1A. Its high degree of similarity with the original tumor genomically and proteomically, as well as the high level of LOH, make this an interesting cell line for O-CCC research. It has been deposited with Ximbio.&quot;,
    &quot;journal&quot;: &quot;Cancer Med&quot;,
    &quot;pub_date&quot;: &quot;2018-09-01&quot;,
    &quot;doi&quot;: &quot;10.1002/cam4.1724&quot;,
    &quot;impact_factor&quot;: 3.1,
    &quot;similarity&quot;: 0.6896477654221516
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6797766764582212,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33376347&quot;,
    &quot;title&quot;: &quot;Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic&quot;,
    &quot;abstract&quot;: &quot;Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1-2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation status seems to be associated with the development of brain metastases from ovarian cancer and these patients may benefit from treatment with PARP (poly ADP ribose polymerase) inhibitors. Here is a case where a Chinese female patient diagnosed with high-grade serous ovarian cancer with brain metastases was detected to have known germline ATM mutation and somatic BRCA2 mutation. The patient underwent whole brain radiotherapy and systemic chemotherapy, commenced niraparib as maintenance treatment and then presented considerable clinical and radiological response.&quot;,
    &quot;journal&quot;: &quot;Onco Targets Ther&quot;,
    &quot;pub_date&quot;: &quot;2020-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/OTT.S281302&quot;,
    &quot;impact_factor&quot;: 2.8,
    &quot;similarity&quot;: 0.6797766764582212
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6724875359821669,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;26774475&quot;,
    &quot;title&quot;: &quot;Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.&quot;,
    &quot;abstract&quot;: &quot;High-grade serous ovarian carcinomas (HGSOCs) with BRCA1/2 mutations exhibit improved outcome and sensitivity to double-strand DNA break (DSB)-inducing agents (i.e., platinum and poly(ADP-ribose) polymerase inhibitors [PARPis]) due to an underlying defect in homologous recombination (HR). However, resistance to platinum and PARPis represents a significant barrier to the long-term survival of these patients. Although BRCA1/2-reversion mutations are a clinically validated resistance mechanism, they account for less than half of platinum-resistant BRCA1/2-mutated HGSOCs. We uncover a resistance mechanism by which a microRNA, miR-622, induces resistance to PARPis and platinum in BRCA1 mutant HGSOCs by targeting the Ku complex and restoring HR-mediated DSB repair. Physiologically, miR-622 inversely correlates with Ku expression during the cell cycle, suppressing non-homologous end-joining and facilitating HR-mediated DSB repair in S phase. Importantly, high expression of miR-622 in BRCA1-deficient HGSOCs is associated with worse outcome after platinum chemotherapy, indicating microRNA-mediated resistance through HR rescue.&quot;,
    &quot;journal&quot;: &quot;Cell Rep&quot;,
    &quot;pub_date&quot;: &quot;2016-01-26&quot;,
    &quot;doi&quot;: &quot;10.1016/j.celrep.2015.12.046&quot;,
    &quot;impact_factor&quot;: 6.9,
    &quot;similarity&quot;: 0.6724875359821669
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6685709713063575,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;38555285&quot;,
    &quot;title&quot;: &quot;The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.&quot;,
    &quot;abstract&quot;: &quot;The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with measurable and biopsiable disease (cohort 5), or without biopsiable disease (cohort 6). The primary endpoint was objective response rate (ORR). Secondary outcomes were safety and progression-free survival (PFS). 49 heavily pretreated patients were enrolled (24 in cohort 5, 25 in cohort 6). Among the 39 RECISTv1.1-evaluable patients, ORR was 33.3% in cohort 5 and 28.6% in cohort 6. Primary endpoint was not evaluable due to early stop of the trial. The median PFS was 4Â months in cohort 5 and 6Â months in cohort 6. Toxicity was manageable. Translational research was an exploratory endpoint. Potential biomarkers were investigated using pre-treatment fresh biopsies and serial blood samples. Transcriptomic analysis revealed high levels of DNA replication-related genes (POLA1, POLE, GINS3) associated with lack of clinical benefit [defined post-hoc as PFS &lt;Â 6 months]. Subsequent preclinical experiments demonstrated significant cytotoxicity of POLA1 silencing in combination with CHK1i in platinum-resistant HGSOC cell line models. Therefore, POLA1 expression may be predictive for CHK1i resistance, and the concurrent POLA1 inhibition may improve the efficacy of CHK1i monotherapy in this hard-to-treat population, deserving further investigation.&quot;,
    &quot;journal&quot;: &quot;Nat Commun&quot;,
    &quot;pub_date&quot;: &quot;2024-03-30&quot;,
    &quot;doi&quot;: &quot;10.1038/s41467-024-47215-6&quot;,
    &quot;impact_factor&quot;: 15.7,
    &quot;similarity&quot;: 0.6685709713063575
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6674334830332206,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;36591227&quot;,
    &quot;title&quot;: &quot;Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radiotherapy and a few cycles of chemotherapy with an extremely durable response even after cessation of immunotherapy for 3 years at the time of publication.&quot;,
    &quot;journal&quot;: &quot;Front Immunol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fimmu.2022.1079253&quot;,
    &quot;impact_factor&quot;: 5.9,
    &quot;similarity&quot;: 0.6674334830332206
  }
]</pre>
    <h3>Evidence Digest (1:1 per RAG result)</h3>
    <pre>- Adjuvant platinum-based chemotherapy improves survival in ovarian carcinoma overall, but a clear survival benefit in early-stage endometrial-type histologies is uncertain; high-grade endometrioid carcinoma behaves prognostically similar to highâ€‘grade serous carcinoma, which typically justifies systemic adjuvant treatment when stage or risk factors are high. [1] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]

- Fertility-sparing in vivo ovarian tissue preservation is stratified by epithelial ovarian cancer histology and FIGO stage; indications are more permissive for borderline tumors and some lowâ€‘grade subtypes in stage I, while highâ€‘grade serous and other poorâ€‘prognosis subtypes have more restrictive or contraindicated preservation recommendations, guiding whether ovarian tissue can safely be conserved or cryopreserved. [2] [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17]

- For advanced ovarian carcinoma at initial evaluation, contrast-enhanced CT, MRI, or PETâ€‘CT with a structured radiology report are all acceptable imaging options, with expert ultrasound as an adjunct; MDT planning should ensure at least one highâ€‘quality crossâ€‘sectional modality plus standardized reporting before deciding on surgery or systemic therapy. [3] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 8]

- In patients with ovarian neoplasms and poor prognostic features, the decision to preserve ovaries or ovarian tissue must balance the potential oncologic risk (including the natural history of the specific histology and stage) against fertility benefits; in some aggressive histologies/stages, guidelines caution that ovarian preservation itself may be inadvisable. [4] [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17]

- In recurrent epithelial ovarian cancer, choice between PARP inhibitors and antiâ€‘VEGF agents at relapse should consider histotype, BRCA1/2 mutation status, prior PARP or bevacizumab exposure, and cumulative platinum exposure, as these affect expected benefit and toxicity; prior extensive platinum can attenuate efficacy in later lines and shapes maintenance strategy. [5] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]

- A novel ovarian clear cell carcinoma cell line (NUCOLL43) with high loss of heterozygosity and genomic similarity to the primary tumor shows distinct drug sensitivities, underscoring that clear cell carcinoma has unique biology and may benefit from nonâ€‘standard regimens; MDTs should consider histology-specific evidence and clinical trials for clear cell disease rather than extrapolating from highâ€‘grade serous data. [6] [@pubmed | 30109783]

- Brain metastases from epithelial ovarian cancer are rare (â‰ˆ1â€“2.5%), and multimodal local therapy (surgery, irradiation) plus systemic treatment can yield benefit but outcomes are generally poor; BRCA/HRR mutation status may guide the use of PARP inhibitors such as niraparib as maintenance in selected cases with ATM/BRCA alterations, warranting molecular testing in metastatic presentations. [7] [@pubmed | 33376347]

- Overexpression of miRâ€‘622 in BRCA1â€‘mutant highâ€‘grade serous ovarian carcinoma restores homologous recombination and induces resistance to both platinum and PARP inhibitors, indicating that molecular resistance mechanisms can negate the usual chemosensitivity of BRCAâ€‘mutant disease; MDTs should consider clinical signs of early platinum/PARP resistance as a prompt to switch to alternative strategies and, where available, enroll in trials targeting DNA damage response. [8] [@pubmed | 26774475]

- The phase 2 NCT02203513 trial of the CHK1 inhibitor prexasertib in BRCAâ€‘wildâ€‘type, platinumâ€‘resistant recurrent highâ€‘grade serous ovarian carcinoma demonstrated clinical activity, supporting CHK1 inhibition as a potential option in heavily pretreated, platinumâ€‘resistant BRCAâ€‘wildâ€‘type disease and as a rationale for referral to relevant clinical trials. [9] [@pubmed | 38555285]

- A reported case of platinumâ€‘refractory metastatic endometrial clear cell carcinoma achieved a durable response to pembrolizumab combined with localized radiotherapy, suggesting a possible abscopal effect; for MSIâ€‘high, TMBâ€‘high, or PDâ€‘L1â€“positive clear cell endometrial/ovarian tumors, MDTs should consider immunotherapy and integration of radiotherapy to potentially enhance systemic responses, preferably within trial settings. [10] [@pubmed | 36591227]</pre>
  </details>

  <details class='mt mermaid-container' open><summary>Pipeline Flow</summary><div class='mermaid-chart'>flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]</div></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:22.221310&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:22.221880&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;2a31f255c155&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:22.490094&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:33.635211&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:33.640799&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=åµå·¢ç™Œå¤å‘; histology=é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=&lt;0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:43.413272&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Recurrent platinum-resistant ovarian clear cell carcinoma with pelvic, presacral, liver and possible bone metastases; Ki-67 60%; HRD-negative, BRCA1/2-negative, germline ATM p.Y316C; no major organ dysfunction reported; histology: clear cell carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:43.413276&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:43.413278&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:43.413279&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:54.042486&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:54.042562&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:57.709455&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 563
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:01:57.709508&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:02:00.409664&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 628
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:02:00.409728&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:02:02.651158&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 576
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:02:02.651231&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:02:05.922694&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 442
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:02:05.922792&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:02:08.063994&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 510
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:03:30.108036&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2583
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:03:30.109297&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:03:33.589466&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: true
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:03:33.589483&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:03:43.288680&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 3095
    }
  }
]</pre>
  </details>

  <!-- Mermaid.js for flowchart rendering -->
  <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      mermaid.initialize({
        startOnLoad: true,
        theme: 'default',
        flowchart: {
          useMaxWidth: true,
          htmlLabels: true,
          curve: 'basis'
        },
        securityLevel: 'loose'
      });
      // Re-render mermaid charts in .mermaid-chart containers
      document.querySelectorAll('.mermaid-chart').forEach(function(el) {
        el.classList.add('mermaid');
      });
      mermaid.init(undefined, '.mermaid-chart');
    });
  </script>
</body>
</html>
